Skip to main content
Medical information Clinical review pending

Genetic Testing

cKIT Mutation Screening Exons 9 11 13 17 AML

This genetic test identifies specific mutations in the cKIT gene (Exons 9, 11, 13, 17) associated with Acute Myeloid Leukemia (AML), aiding in treatment planning and prognosis.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
2ml of peripheral blood collected in an EDTA tube.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test. Confirm with the laboratory before booking.
Test priceKSh 15,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the cKIT Mutation Screening Exons 9 11 13 17 AML test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of Acute Myeloid Leukemia (AML)
  • ✓Prognosis assessment in AML patients
  • ✓Guiding treatment decisions in AML
  • ✓Identifying potential targets for therapy in AML
  • ✓Patients with symptoms suggestive of AML (e.g., fatigue, fever, infections)
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the cKIT gene associated with AML. This information can assist healthcare providers in understanding the potential behavior of the leukemia, predicting response to certain therapies, and guiding personalized treatment decisions.
The cKIT Mutation Screening Exons 9 11 13 17 AML is a diagnostic test used to detect specific genetic mutations within the cKIT gene. These mutations are frequently found in patients with Acute Myeloid Leukemia (AML). Identifying these mutations is important because they can influence how the leukemia behaves and how well it responds to certain treatments. This information helps doctors tailor treatment plans for better patient outcomes. The test focuses on specific sections (exons) of the cKIT gene known to be commonly affected in AML. Understanding the presence or absence of these mutations provides valuable insights for managing the condition.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test. Confirm with the laboratory before booking.
Sample2ml of peripheral blood collected in an EDTA tube.
MethodologySanger Sequencing.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test screens for mutations in specific exons (9, 11, 13, 17) of the cKIT gene. Mutations outside these regions may not be detected. The test does not provide information on all possible genetic alterations in AML. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The cKIT gene provides instructions for making a protein involved in the growth and development of certain types of cells, including those in the blood and bone marrow. Mutations in this gene can contribute to the development of leukemia.
These specific sections (exons) of the cKIT gene are known locations where mutations frequently occur in patients with Acute Myeloid Leukemia (AML). Testing these areas helps identify common genetic changes associated with the disease.
The results help your doctor understand more about your specific type of AML. This information can guide decisions about the most effective treatment options and help predict the likely course of the disease.
Yes, a doctor's prescription is required to order this test. Please consult your physician to determine if this test is appropriate for you.
A small sample of your blood (2ml) will be collected in a specific tube (EDTA tube). This is a routine blood draw procedure.
We have laboratory branches in Nairobi, Mombasa, and Kisumu. We also offer home sample collection services for your convenience. Please contact us to arrange testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp